PDF(Pubmed)
Abstract：
UNASSIGNED: The purpose of this study is to compare the application value of 68Ga-FAPI and 18F-FDG PET/CT in primary and metastatic lesions of abdominal and pelvic malignancies (APMs).
UNASSIGNED: The search, limited to the earliest available date of indexing through 31 July 2022, was performed on PubMed, Embase, and Cochrane Library databases using a data-specific Boolean logic search strategy. We calculated the detection rate (DR) of 68Ga-FAPI and 18F-FDG PET/CT in the primary staging and recurrence of APMs, and pooled sensitivities/specificities based on lymph nodes or distant metastases.
UNASSIGNED: We analyzed 473 patients and 2775 lesions in the 13 studies. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in evaluating the primary staging and recurrence of APMs were 0.98 (95% CI: 0.95-1.00), 0.76 (95% CI: 0.63-0.87), and 0.91(95% CI: 0.61-1.00), 0.56 (95% CI: 0.44-0.68), respectively. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in primary gastric cancer and liver cancer were 0.99 (95% CI: 0.96-1.00), 0.97 (95% CI: 0.89-1.00) and 0.82 (95% CI: 0.59-0.97), 0.80 (95% CI: 0.52-0.98), respectively. The pooled sensitivities of 68Ga-FAPI and 18F-FDG PET/CT in lymph nodes or distant metastases were 0.717(95% CI: 0.698-0.735) and 0.525(95% CI: 0.505-0.546), and the pooled specificities were 0.891 (95% CI: 0.858-0.918) and 0.821(95% CI: 0.786-0.853), respectively.
UNASSIGNED: This meta-analysis concluded that 68Ga-FAPI and 18F-FDG PET/CT had a high overall diagnostic performance in detecting the primary staging and lymph nodes or distant metastases of APMs, but the detection ability of 68Ga-FAPI was significantly higher than that of 18F-FDG. However, the ability of 68Ga-FAPI to diagnose lymph node metastasis is not very satisfactory, and is significantly lower than that of distant metastasis.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42022332700.
UNASSIGNED: The search, limited to the earliest available date of indexing through 31 July 2022, was performed on PubMed, Embase, and Cochrane Library databases using a data-specific Boolean logic search strategy. We calculated the detection rate (DR) of 68Ga-FAPI and 18F-FDG PET/CT in the primary staging and recurrence of APMs, and pooled sensitivities/specificities based on lymph nodes or distant metastases.
UNASSIGNED: We analyzed 473 patients and 2775 lesions in the 13 studies. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in evaluating the primary staging and recurrence of APMs were 0.98 (95% CI: 0.95-1.00), 0.76 (95% CI: 0.63-0.87), and 0.91(95% CI: 0.61-1.00), 0.56 (95% CI: 0.44-0.68), respectively. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in primary gastric cancer and liver cancer were 0.99 (95% CI: 0.96-1.00), 0.97 (95% CI: 0.89-1.00) and 0.82 (95% CI: 0.59-0.97), 0.80 (95% CI: 0.52-0.98), respectively. The pooled sensitivities of 68Ga-FAPI and 18F-FDG PET/CT in lymph nodes or distant metastases were 0.717(95% CI: 0.698-0.735) and 0.525(95% CI: 0.505-0.546), and the pooled specificities were 0.891 (95% CI: 0.858-0.918) and 0.821(95% CI: 0.786-0.853), respectively.
UNASSIGNED: This meta-analysis concluded that 68Ga-FAPI and 18F-FDG PET/CT had a high overall diagnostic performance in detecting the primary staging and lymph nodes or distant metastases of APMs, but the detection ability of 68Ga-FAPI was significantly higher than that of 18F-FDG. However, the ability of 68Ga-FAPI to diagnose lymph node metastasis is not very satisfactory, and is significantly lower than that of distant metastasis.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42022332700.
摘要：
UNASSIGNED：本研究的目的是比较68Ga-FAPI和18F-FDGPET/CT在腹部和盆腔恶性肿瘤（APMs）的原发和转移性病变中的应用价值。
未经评估：搜索，仅限于截至2022年7月31日的最早可用索引日期，在PubMed上进行，Embase,和CochraneLibrary数据库使用数据特定的布尔逻辑搜索策略。我们计算了68Ga-FAPI和18F-FDGPET/CT在APM的原发分期和复发中的检出率（DR），以及基于淋巴结或远处转移的合并敏感性/特异性。
UNASSIGNED：我们分析了13项研究中的473例患者和2775个病灶。68Ga-FAPI和18F-FDGPET/CT评估APMs的原发分期和复发的DR为0.98(95%CI:0.95-1.00),0.76（95%CI：0.63-0.87），和0.91（95%CI：0.61-1.00），0.56（95%CI：0.44-0.68），分别。原发性胃癌和肝癌中68Ga-FAPI和18F-FDGPET/CT的DR分别为0.99(95%CI:0.96-1.00),0.97（95%CI：0.89-1.00）和0.82（95%CI：0.59-0.97），0.80（95%CI：0.52-0.98），分别。68Ga-FAPI和18F-FDGPET/CT在淋巴结或远处转移中的合并敏感性为0.717（95％CI：0.698-0.735）和0.525（95％CI：0.505-0.546），合并的特异性为0.891（95％CI：0.858-0.918）和0.821（95％CI：0.786-0.853），分别。
UNASSIGNED：这项荟萃分析得出结论，68Ga-FAPI和18F-FDGPET/CT在检测APMs的原发分期和淋巴结或远处转移方面具有较高的总体诊断性能，但68Ga-FAPI的检测能力明显高于18F-FDG。然而,68Ga-FAPI诊断淋巴结转移的能力不是很令人满意，且明显低于远处转移。
UNASSIGNED：https://www。crd.约克。AC.英国/普华永道/，标识符CRD42022332700。
未经评估：搜索，仅限于截至2022年7月31日的最早可用索引日期，在PubMed上进行，Embase,和CochraneLibrary数据库使用数据特定的布尔逻辑搜索策略。我们计算了68Ga-FAPI和18F-FDGPET/CT在APM的原发分期和复发中的检出率（DR），以及基于淋巴结或远处转移的合并敏感性/特异性。
UNASSIGNED：我们分析了13项研究中的473例患者和2775个病灶。68Ga-FAPI和18F-FDGPET/CT评估APMs的原发分期和复发的DR为0.98(95%CI:0.95-1.00),0.76（95%CI：0.63-0.87），和0.91（95%CI：0.61-1.00），0.56（95%CI：0.44-0.68），分别。原发性胃癌和肝癌中68Ga-FAPI和18F-FDGPET/CT的DR分别为0.99(95%CI:0.96-1.00),0.97（95%CI：0.89-1.00）和0.82（95%CI：0.59-0.97），0.80（95%CI：0.52-0.98），分别。68Ga-FAPI和18F-FDGPET/CT在淋巴结或远处转移中的合并敏感性为0.717（95％CI：0.698-0.735）和0.525（95％CI：0.505-0.546），合并的特异性为0.891（95％CI：0.858-0.918）和0.821（95％CI：0.786-0.853），分别。
UNASSIGNED：这项荟萃分析得出结论，68Ga-FAPI和18F-FDGPET/CT在检测APMs的原发分期和淋巴结或远处转移方面具有较高的总体诊断性能，但68Ga-FAPI的检测能力明显高于18F-FDG。然而,68Ga-FAPI诊断淋巴结转移的能力不是很令人满意，且明显低于远处转移。
UNASSIGNED：https://www。crd.约克。AC.英国/普华永道/，标识符CRD42022332700。
